Free Trial

Liquidia Q1 2024 Earnings Report

Liquidia logo
$11.10 +0.51 (+4.82%)
(As of 12/20/2024 05:31 PM ET)

Liquidia EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

Liquidia Revenue Results

Actual Revenue
$2.97 million
Expected Revenue
$4.31 million
Beat/Miss
Missed by -$1.34 million
YoY Revenue Growth
N/A

Liquidia Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Your bank is lying to you. (Ad)

You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

Liquidia Earnings Headlines

Liquidia initiated with an Overweight at Wells Fargo
Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $24.00
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Liquidia Technologies (LQDA) Gets a Buy from Scotiabank
See More Liquidia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia and other key companies, straight to your email.

About Liquidia

Liquidia (NASDAQ:LQDA), a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

View Liquidia Profile

More Earnings Resources from MarketBeat

Upcoming Earnings